跳至主要内容
临床试验/CTRI/2017/06/008872
CTRI/2017/06/008872尚未招募2 期

A Pilot study of Leflunomide to prevent Cytomegalovirus (CMV) reactivation in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) - Not applicable

Institutional support Academic study Christian Medicaol College Vellore0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients undergoing Haplo-identical stem cell transplantation (HHSCT)
  • 2. Patients undergoing matched unrelated donor transplantation (MUD HSCT)
  • 3. Patients willing to sign informed consent
  • 4. Patients > 2 years of age [willing to swallow oral tablets]
  • 5. Patient should be CMV IgG + prior to HSCT.
  • 6. Patients with stable engraftment [ANC >500/mm3 on 2 occasions 1 day apart]

排除标准

  • 1.Patients undergoing matched sibling donor transplantation
  • 2.Patients who are CMV IgG negative prior to HSCT
  • 3.Patients who are unable to swallow tablets
  • 4.Patients will liver function tests > 5 ULN [SGPT >200, SGOT >200, Total Billirubin > 2 mg%] post engraftment
  • 5.Patients who have already reactivated CMV prior to initiation of leflunomide.

研究者

发起方
Institutional support Academic study Christian Medicaol College Vellore

相似试验